Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome

NCT00542269 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

178

Enrollment

INDUSTRY

Sponsor class

Stopped Early termination of the study due to slow recruitment.

Conditions

Hypertension With Metabolic Syndrome

Interventions

DRUG: Amlodipine
DRUG: Aliskiren
DRUG: Ramipril

Sponsor

Novartis